MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · Real-Time Price · USD
9.41
+0.19 (2.06%)
At close: May 1, 2026, 4:00 PM EDT
9.23
-0.18 (-1.91%)
After-hours: May 1, 2026, 7:50 PM EDT
MeiraGTx Holdings Revenue
In the year 2025, MeiraGTx Holdings had annual revenue of $81.39M with 144.57% growth. MeiraGTx Holdings had revenue of $75.36M in the quarter ending December 31, 2025, with 252.33% growth.
Revenue (ttm)
$81.39M
Revenue Growth
+144.57%
P/S Ratio
10.70
Revenue / Employee
$201,963
Employees
403
Market Cap
870.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 81.39M | 48.11M | 144.57% |
| Dec 31, 2024 | 33.28M | 19.26M | 137.42% |
| Dec 31, 2023 | 14.02M | -1.90M | -11.95% |
| Dec 31, 2022 | 15.92M | -21.78M | -57.77% |
| Dec 31, 2021 | 37.70M | 22.14M | 142.25% |
| Dec 31, 2020 | 15.56M | 2.27M | 17.09% |
| Dec 31, 2019 | 13.29M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 348.97M |
| Theravance Biopharma | 107.46M |
| ARS Pharmaceuticals | 84.28M |
| Arbutus Biopharma | 14.08M |
| Evommune | 13.00M |
| Janux Therapeutics | 10.00M |
MGTX News
- 17 days ago - Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson - Benzinga
- 17 days ago - MeiraGTx Holdings Transcript: KOL event - Transcripts
- 17 days ago - MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares - GlobeNewsWire
- 17 days ago - MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) - GlobeNewsWire
- 17 days ago - MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia - GlobeNewsWire
- 19 days ago - MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026 - GlobeNewsWire
- 5 weeks ago - MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results - GlobeNewsWire
- 5 weeks ago - MeiraGTx Holdings Transcript: RBC Capital Markets Virtual Ophthalmology Conference - Transcripts